Last reviewed · How we verify

IMOVAX POLIO®: Inactive Poliovirus Vaccine

Sanofi Pasteur, a Sanofi Company · FDA-approved active Biologic

IMOVAX POLIO®: Inactive Poliovirus Vaccine is a Inactivated viral vaccine Biologic drug developed by Sanofi Pasteur, a Sanofi Company. It is currently FDA-approved for Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3. Also known as: SP059, IMOVAX POLIO®.

IMOVAX POLIO stimulates the immune system to produce antibodies against all three types of poliovirus by introducing inactivated (killed) virus particles.

IMOVAX POLIO stimulates the immune system to produce antibodies against all three types of poliovirus by introducing inactivated (killed) virus particles. Used for Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3.

At a glance

Generic nameIMOVAX POLIO®: Inactive Poliovirus Vaccine
Also known asSP059, IMOVAX POLIO®
SponsorSanofi Pasteur, a Sanofi Company
Drug classInactivated viral vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhaseFDA-approved

Mechanism of action

The vaccine contains chemically inactivated poliovirus types 1, 2, and 3, which cannot cause disease but trigger a humoral immune response. B cells recognize the viral antigens and produce neutralizing antibodies that protect against infection if the vaccinated person is exposed to wild-type poliovirus. This provides long-lasting immunity without the risk of vaccine-derived poliovirus that can occur with live attenuated vaccines.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about IMOVAX POLIO®: Inactive Poliovirus Vaccine

What is IMOVAX POLIO®: Inactive Poliovirus Vaccine?

IMOVAX POLIO®: Inactive Poliovirus Vaccine is a Inactivated viral vaccine drug developed by Sanofi Pasteur, a Sanofi Company, indicated for Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3.

How does IMOVAX POLIO®: Inactive Poliovirus Vaccine work?

IMOVAX POLIO stimulates the immune system to produce antibodies against all three types of poliovirus by introducing inactivated (killed) virus particles.

What is IMOVAX POLIO®: Inactive Poliovirus Vaccine used for?

IMOVAX POLIO®: Inactive Poliovirus Vaccine is indicated for Prevention of poliomyelitis caused by poliovirus types 1, 2, and 3.

Who makes IMOVAX POLIO®: Inactive Poliovirus Vaccine?

IMOVAX POLIO®: Inactive Poliovirus Vaccine is developed and marketed by Sanofi Pasteur, a Sanofi Company (see full Sanofi Pasteur, a Sanofi Company pipeline at /company/sanofi).

Is IMOVAX POLIO®: Inactive Poliovirus Vaccine also known as anything else?

IMOVAX POLIO®: Inactive Poliovirus Vaccine is also known as SP059, IMOVAX POLIO®.

What drug class is IMOVAX POLIO®: Inactive Poliovirus Vaccine in?

IMOVAX POLIO®: Inactive Poliovirus Vaccine belongs to the Inactivated viral vaccine class. See all Inactivated viral vaccine drugs at /class/inactivated-viral-vaccine.

What development phase is IMOVAX POLIO®: Inactive Poliovirus Vaccine in?

IMOVAX POLIO®: Inactive Poliovirus Vaccine is FDA-approved (marketed).

What are the side effects of IMOVAX POLIO®: Inactive Poliovirus Vaccine?

Common side effects of IMOVAX POLIO®: Inactive Poliovirus Vaccine include Injection site reactions (pain, redness, swelling), Fever, Myalgia, Headache.

Related